Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant for Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1
NCT04886518Phase 2Completed
- Sponsor
- Harmony Biosciences
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of pitolisant in myotonic dystrophy type 1 (DM1) and Excessive Daytime Sleepiness (EDS) (3 arms), sponsored by Harmony Biosciences. Primary endpoint: Daytime Sleepiness Scale at 11 weeks. Started Jun 2021; status: completed.
02
Drugs
pitolisant
03
Conditions
myotonic dystrophy type 1 (DM1)Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT04886518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886518.